ERBB2 and triple-negative breast carcinoma: Findings have shown short-term survival outcomes to be considerably lower for patients with triple-negative breast cancer than for patients eligible to receive HER2 targeted or endocrine therapies.56 Differential survival by screening status in relation to disease subtype is yet to be evaluated in real-world populations.